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polyRad – protection Against free 
Radical Damage
Hannah Kim1,5, Yin tse2,5, Andrew Webb2,5, Ethan Mudd2,5, Muhammad Raisul Abedin2, 
Melanie Mormile1, Subhadeep Dutta3, Kaushal Rege4 & Sutapa Barua2 ✉
The effects of elevated levels of radiation contribute to the instability of pharmaceutical formulations in 
space compared to those on earth. Existing technologies are ineffective at maintaining the therapeutic 
efficacies of drugs in space. Thus, there is an urgent need to develop novel space-hardy formulations for 
preserving the stability and efficacy of drug formulations. This work aims to develop a novel approach 
for the protection of space pharmaceutical drug molecules from the radiation-induced damage to help 
extend or at least preserve their structural integrity and potency. To achieve this, free radical scavenging 
antioxidant, Trolox was conjugated on the surface of poly-lactic-co-glycolic acid (PLGA) nanoparticles 
for the protection of a candidate drug, melatonin that is used as a sleep aid medication in International 
Space Station (ISS). Melatonin-PLGA-PLL-Trolox nanoparticle as named as PolyRad was synthesized 
employing single oil in water (o/w) emulsion solvent evaporation method. PolyRad is spherical in shape 
and has an average diameter of ~600 nm with a low polydispersity index of 0.2. PolyRad and free 
melatonin (control) were irradiated by UV light after being exposed to a strong oxidant, hydrogen 
peroxide (H2o2). Bare melatonin lost ~80% of the active structure of the drug following irradiation with 
UV light or treatment with H2o2. In contrast, PolyRad protected >80% of the active structure of 
melatonin. The ability of PolyRad to protect melatonin structure was also carried out using 0, 1, 5 and 
10 Gy gamma radiation. Gamma irradiation showed >98% active structures of melatonin encapsulated 
in PolyRads. Drug release and effectiveness of melatonin using PolyRad were evaluated on human 
umbilical vein endothelial cells (HUVEC) in vitro. Non-irradiated PolyRad demonstrated maximum drug 
release of ~70% after 72 h, while UV-irradiated and H2o2-treated PolyRad showed a maximum drug 
release of ~85%. Cytotoxicity of melatonin was carried out using both live/dead and MTT assays. 
Melatonin, non-radiated PolyRad and irradiated PolyRad inhibited the viability of HUVEC in a dose-
dependent manner. Cell viability of melatonin, PolyRad alone without melatonin (PolyRad carrier 
control), non-radiated PolyRad, and irradiated PolyRad were ~98, 87, 75 and 70%, respectively at a 
concentration ~ 0.01 mg ml/  ( g ml10 / ). Taken together, PolyRad nanoparticle provides an attractive 
formulation platform for preventing damage to pharmaceutical drugs in potential space mission 
applications.
As NASA prepares for exploration missions beyond low Earth orbit with no opportunities for resupply, pharma-
ceutical instability may present significant risk to the crew health due to the loss of efficacy over time. Astronauts 
suffer from sleep disruption during space flight that can affect their mental and physical health in performing 
routine work1–4. Therefore, mitigation against the effects of space radiation on pharmaceutical drugs is necessary 
for the success of long-term space missions. NASA is primarily concerned with the health risks for astronaut 
exposure to radiation and other flight infections. NASA estimates that a 30-month mission to Mars would expose 
astronauts to over 900 millisieverts (mSv) (1000 mSv = 1 gray), far beyond safe or acceptable Occupational Safety 
and Health Administration (OSHA) limits of 50 mSv in the United States5,6. Persistent radiation induces oxidative 
stress associated with the central nervous system, blood coagulation abnormalities, fibrosis, heart failures, gene 
expression changes, cancer as long-term effects and other physiological abnormalities7–10.
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High energy radiation and oxidative stress due to UV and gamma radiation induce radiolysis of water gener-
ating highly reactive hydrogen (H•) and hydroxyl (OH•) radicals that diffuse to other molecules and react with 
particular chemical groups resulting in a loss of biochemical activity11. There are three mechanisms of radiation 
damage caused by OH• in the chemical structure of a compound: the abstraction of H−  by OH• leaving an 
unpaired electron on the carbon atom, the formation of a hydroxy derivative by breaking double bonds (e.g., 
− = −C C ) and the electron transfer from anionic groups (e.g., −Cl ) to OH•11. The production of reactive OH• 
has been demonstrated by chemical means such as UV photolysis of hydrogen peroxide (H2O2) and gamma irra-
diation using colbalt-60 (60Co) or cesium 137 (137Cs)12–17. The effects of radiation on a variety of pharmaceutical 
drug molecules have been studied using either gamma radiation or H2O2 hydrolysis by UV light at different doses 
that show linear proportionality of the decreasing amount of active substances with the dose of radiation18–22.
One way to countermeasure the adverse effects of radiation is by creating an artificial shield. Numerous exper-
imental investigations and theoretical studies have reported the use of a variety of shielding materials that include 
concrete, polymer composites, heavy metals such as lead, composites of lead oxide, tungsten and tin, etc. for 
attenuation and absorption of the undesired radiations23–25. However, the materials are heavy and bulky that add 
unwanted features to most spacecraft applications. Materials with lightweight and low volumes are preferred 
due to space and maneuverability constraints imposed by the vehicles26. Polymers are preferred for their radi-
ation resistant and neutron shielding capabilities27–32, however, their mechanical and thermal stability can be 
compromised by the heat generated from irradiation27. A combination of metal and polymer microparticles and 
nanoparticles using radiation-resistant polymer has shown to improve the radiation-resistance properties of the 
composite material28,33–42. Based on the previous studies by others, it is hypothesized that polymer nanoparticles 
can be designed to minimize the radiation induced damage by scavenging free radicals with the use of antiox-
idants. Other medical countermeasures including small molecule antioxidants, such as radioprotective agents 
such as melatonin, Trolox, vitamin C, vitamin E, cysteine and others, have also been used as radioprotective 
agents43–46.
The objective of this work is to engineer a self-protected medication using a polymeric nanoparticle assembly 
of a biocompatible polymer, poly (lactic-co-glycolic acid) (PLGA), a free radical scavenger molecule (Trolox) 
and a linker poly-l-lysine (PLL) (Fig. 1a). Melatonin is used as a model relevant to space flight missions. In this 
design, melatonin was encapsulated in the core of PLGA polymer nanoparticles using an oil/water single emul-
sion solvent evaporation method. In a separate reaction, Trolox was conjugated to PLL via EDC/NHS chemis-
try for conjugating the carboxylates in Trolox with the amines in PLL (Fig. 1b). The residual amine groups on 
PLL-Trolox were further conjugated on the surface of melatonin-loaded PLGA nanoparticles via the same pro-
cess of EDC/NHS reaction. It is hypothesized that Trolox conjugation on the surface of nanoparticles (PolyRad) 
protects the chemical stability of melatonin during spaceflight mimicking conditions that generate excessive 
radiation-induced free radicals through its potential for antioxidant capacity and free radical scavenging activity. 
We further hypothesize that the PolyRad approach offers great benefits by increasing the specific surface area and 
accelerating the dissolution velocities of drug molecules, which ultimately has a beneficial impact on the drug 
release and associated bioavailability.
Materials and Methods
Materials. All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified.
Synthesis of PolyRad nanoparticles. Melatonin-PLGA-PLL-Trolox (PolyRad) nanoparticles were 
prepared in three steps: entrapment of melatonin in PLGA (melatonin-PLGA), conjugation of Trolox 
with PLL (PLL-Trolox), and surface conjugation of the PLL-Trolox on melatonin-PLGA nanoparticles 
(melatonin-PLGA-PLL-Trolox). Melatonin (N-acetyl-5-methoxytryptamine) was encapsulated in PLGA polymer 
using water-in-oil (w/o) emulsion phase separation method (Fig. 1a)47–49. Briefly, 1 ml of each 1% (w/v) of mela-
tonin dissolved in DMSO and 5% (w/v) of PLGA polymer dissolved in dichloromethane (DCM) were added to 
Figure 1. Design of PolyRad with the core of PLGA particles conjugated with PLL and Trolox. (a) Schematic 
of solvent diffusion method to synthesize melatonin encapsulated PLGA nanoparticles. (b) The surface of the 
particles was conjugated with PLL-Trolox conjugates which were synthesized separately in a parallel reaction. It 
is hypothesized that the nanoparticle formulation protects melatonin from photochemical degradation.
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20 ml of 1% (w/v) polyvinyl alcohol (PVA) solution using a syringe pump. The flow rate of 1 ml/h was maintained 
under sonication and homogenization. The nanoparticle suspension was stirred (350 rpm) overnight (for about 
18 h) to remove DCM by evaporation.
Conjugation of Trolox to PLL was carried out by activation of carboxyl groups in Trolox followed by reaction 
with the primary amine groups of PLL polymer resulting in the formation of amide bonds (Fig. 1b). Briefly, 
4 mg of 1-ethyl-3-3-dimethylaminopropyl-carbodiimide (EDC) was directly added to 1 ml of 10 mg/ml Trolox 
dissolved in phosphate-buffered saline (PBS) of pH 7.4. Immediately, 6 mg of N-hydroxysuccinimide (NHS) was 
added to the reaction. The reaction solution was mixed gently, maintained at pH 7.4, and left at room tempera-
ture (R.T.; 25 °C) to react for 15 min. PLL (11.5 mg) was added to the solution that was incubated at R.T. for 2 h 
while shaking (450 rpm). The residual primary amine groups of PLL-Trolox were conjugated to the surface of 
melatonin-PLGA nanoparticles using EDC/NHS chemistry. The final reaction solution was filtered using 100 kDa 
Amicon Ultra-4 centrifugal filters to remove any excess reagents.
PolyRad characterization: size, surface charge, and melatonin encapsulation efficiency. The 
size and surface charge of particles before and after PLL-Trolox conjugation on melatonin encapsulated PLGA 
nanoparticles were measured using dynamic light scattering (DLS) and zeta potential measurements, respectively 
using a NanoSeries Zetasizer ZS 90 (Malvern). Samples were prepared in deionized (DI) water. Encapsulation 
of melatonin in PolyRad nanoparticles was assessed by measuring the absorbance at 300 nm using a microplate 
reader (BioTek Synergy 2) and a melatonin standard curve (S.I. Figure 1). The percentage of melatonin encapsu-
lation capacity was calculated using the following Eq. 1:
=
− −
×encapsulation efficiency M M M
M




where, M0 = Initial melatonin mass, Mu = Melatonin mass in unwashed suspension and Ms = Melatonin mass in 
supernatant.
Characterization of PLGA-PLL-Trolox formulation using Fourier Transform Infrared (FT-IR) 
Spectroscopy. FTIR spectroscopy was used to confirm the structural changes that occurred after PLL-Trolox 
conjugation with PLGA nanoparticles. Samples for FT-IR spectroscopy were prepared by mixing and grinding 
freeze-dried nanoparticles with FT-IR grade potassium bromide (KBr; Alpha Aesar) (w:w ratio of 1:100) to make 
pulverized pellets. FT-IR absorption spectra were obtained using a Thermo Nicolet NEXUS 470 FTIR instrument 
in the wavelength range from 4000 to 400 cm−1 at a resolution of 4 cm−1 using 32 scans per sample. The effect of 
background noise from the ambient air without a sample in place was subtracted from the sample spectra. All 
spectra were analyzed using EZ OMNIC E.S.P v.5.1 software (Thermo Scientific). The resulting FTIR spectra of 
PLGA-PLL-Trolox were compared to individual spectra of PLGA, PLL, and Trolox to characterize the conjuga-
tion reaction based on the intensity or shift of the vibrational bands.
Determination of the composition of melatonin-PLGA-PLL-Trolox (PolyRad) nanoparticles 
using 1H-NMR spectroscopy. For 1H-NMR spectroscopy, 10 mg of PolyRad nanoparticles, melatonin 
alone, PLGA alone, PLL alone, and Trolox alone were dissolved in 750 μl of DMSO-d6 except for PLGA, which 
was dissolved in d-Chloroform. Each solvent was used as the internal reference to determine chemical shifts (δ) 
in ppm. 1H-NMR spectra were then recorded using Bruker advanced III 400 MHz Liquid-State NMR instrument 
at R.T.
Fluorometric Hydroxyl Radical Scavenging Capacity (HOSC) assay. A fluorometric HOSC assay 
was applied to determine the mechanisms of highly reactive free radical absorption by PLGA-PLL-Trolox com-
posite and Trolox alone was used as a standard50. OH• radicals were generated using Fe (III)/H2O2 Fenton-like 
reaction system in a pH 7.4 sodium phosphate buffer51. Assay reactions were carried out in Costar black 96-well 
polystyrene plates and analyzed using a microplate reader (BioTek Synergy 2) with an excitation wavelength of 
485 nm, emission wavelength of 530 nm, and 0.1 s read time for each well with each plate read once per minute 
for 3 h. The reaction mixture contained 170 μl of 9.28 × 10−8 M fluorescein (FL) prepared in 75 mM sodium 
phosphate buffer (pH 7.4), 30 μl of blank or antioxidant, 40 μl of 0.1990 M H2O2 and 60 μl of 3.43 mM FeCl3 added 
in that order50. Trolox concentrations of 20, 40, 60, 80, and 100 μM were used. Relative fluorescence intensity of 
each Trolox standard concentrations were calculated by dividing individual fluorescence readings by the initial 
fluorescence reading at time equal to zero.
Photochemical degradation of melatonin. To examine the resistance to photochemical degradation of 
melatonin, 2 mg of PolyRads containing 2.5 μg melatonin were dissolved in 1 ml 40% acetonitrile-60% water (v/v) 
solvent and spiked with 0.75 mM hydrogen peroxide (H2O2) followed by UV radiation at 254 nm and 39 W spec-
tral output for 0, 1, 2, 4, 6 and 8 h. H2O2 is known to be decomposed into hydroxyl radical (OH•) and superoxide 
ions (O2
.− ) when exposed to UV radiation. Pure melatonin powder was used as a control and were treated with 
0.75 mM H2O2 followed by UV irradiation at every 20 min for up to 2 h. The reaction progress was monitored by 
determination of melatonin concentration and its two degradant products (N1-acetyl-N2-formyl-
5-methoxykynuramine, AFMK and 6-hydroxymelatonin) using Agilent 1260 Liquid Chromatography (LC) 
High-Performance Liquid Chromatography (HPLC) apparatus equipped with Waters C18 column of 4.6 × 
250 mm (particle size 5 μm). The system consisted of a vacuum degasser, a binary pump unit, an autosampler for 
sample injections, a thermostat column compartment, and a photodiode array detector (DAD) for peak analysis 
at 304 nm. The mobile phase used was acetonitrile −25 mM ammonium acetate (40:60, v/v). The system was run 
at ambient temperature (~22 °C) with a flow rate of 1.0 ml/min. Sample injections of 30 μl were taken and 
4Scientific RepoRtS |         (2020) 10:8335  | https://doi.org/10.1038/s41598-020-65247-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
observed for characteristic peaks over 8 min intervals between injections. Quantification of melatonin and degra-
dation products were carried out using calibration curves obtained by repeated injections of standard solutions of 
known concentration.
Gamma irradiation of PolyRad. The effects of gamma irradiation on the chemical structure of melatonin 
were carried out using radioactive cobalt 60 (60Co) isotope of activity 200 mCi. Two sample groups of melatonin 
alone and PolyRad were prepared in 1 ml of 10 mg/ml aqueous solutions and irradiated at 1, 5 and 10 Gray (Gy) 
doses. Non-radiated (0 Gy) melatonin and nanoparticles were used as controls. The samples were lyophilized and 
dissolved in DMSO-d6. The effects of gamma irradiation on the structure of melatonin alone and melatonin in 
PolyRad nanoparticles were investigated using 1H-NMR spectroscopy (Bruker instrument 400 MHz). The spectra 
were calibrated and normalized relative to DMSO-d6 at 25 °C (δ = 0 ppm). After 1H-NMR measurements, the 
relative area under the curves were calculated with respect to non-radiated melatonin standards and plotted as a 
function of radiation doses.
In vitro drug release kinetics. In vitro release of melatonin from non-irradiated and irradiated PolyRad 
was carried out in PBS at pH 7.4. Each 10 mg of PolyRad and melatonin powder were put in separate 1.5 ml centri-
fuge tubes and exposed to 0.75 mM H2O2 followed by UV irradiation for 2 h. PolyRad was suspended in 10 ml PBS 
and kept in a 37 °C water bath. PBS solution of 500 μl was withdrawn at 0, 5, 10, 15 and 30 min and then at 1, 2, 4, 
8, 12, 24, 48 and 72 h. The solution was centrifuged at 1000 rcf for 1 min. The supernatant (150 μl) was put in a 96 
well assay plate in triplicates. PBS was used as a blank. Melatonin concentrations were measured using absorbance 
at 300 nm using the microplate reader and melatonin standard curve. The drug release kinetics data were plotted 
as log cumulative drug release versus log time (Eq. 2).
τ− = − +τ− ∞( )M M b m t klog / log( ) log (2)t( )
where τ−M t( ) is the cumulative drug release at time t , ∞M  is the cumulative drug release at infinite time, 
M M/t( )τ− ∞ is the fractional drug release at time t, τ  is the lag time, b is the fractional drug burst release, k is a 
kinetic constant that measures the drug release rate characteristic of the drug/polymer system, and n is the release 
exponent which characterizes the drug release mechanism52–58.
Melatonin cytotoxicity. To determine and compare the cytotoxicity of melatonin on endothelial cells, 
human umbilical vein endothelial cells (HUVEC) were treated with free melatonin, melatonin-loaded PolyRad 
(carrier control), PolyRad, PolyRad treated with 10 Gy of gamma radiation, and PolyRad treated with 0.75 mM 
of H2O2 followed by 1 h of UV radiation. HUVEC were seeded in Costar 96 well assay plate (sterile, black, 
clear-bottom with lid) at a cell density of 10,000 cells/well. The cells were incubated in PromoCell medium with 
10% FBS and 1% penicillin-streptomycin (10,000 units/ml) at a 37 °C and 5% CO2 incubator. Cells were allowed 
to grow overnight. The cells were incubated for 72 h with melatonin solution control and PolyRad at melatonin 
concentrations of 0.01, 0.1, 1 and 10 mg/ml. PBS was used as a negative control. Untreated viable (live) HUVEC 
were used as a positive control. After 72 h, cells were rinsed with PBS and cellular viability were measured using 
MTT assay (Invitrogen). The reduction of MTT to formazan by viable HUVEC was quantified measuring absorb-
ance at 570 nm. Absorbance of treated cells were measured and calculated by subtracting the mean background 
level of wells containing the medium. The % cell viability was calculated as absorbance ratio of treated cells to live 
cells as shown in Eq. (3):
A A
A A
% cell viability 100
(3)
570 of sample 570 of medium





To visualize cells under fluorescence microscope, live and dead cells were stained using 2 μM calcein AM and 
4 μM of EthD-1, respectively following the manufacturer’s protocol. Images were acquired using a 10X Plan Fluor 
(NA = 0.3) objective equipped with a Carl Zeiss Axio Observer Z1 microscope at excitation/emissions of 470 ± 
40/525 ± 50 and 545 ± 25/605 ± 70, respectively.
Results
Characterization of PolyRad. We synthesized melatonin-encapsulated PLGA nanoparticles with an aver-
age diameter of 325 ± 21 nm (Fig. 2a), polydispersity index (pDI) of 0.07 ± 0.05, and a zeta potential of about 
−23 ± 8.5 mV (Fig. 2b) as confirmed by the DLS analysis. The PLL-Trolox shell attributed to the increase in 
particle size due to the deposition of its complex onto the surface of melatonin-PLGA nanoparticles. The average 
diameter of PLL-Trolox conjugated PolyRad nanoparticles were approximately 90% larger (622 ± 114 nm; Fig. 2c) 
than melatonin-PLGA control nanoparticles without PLL-Trolox shell as seen by the shift in the average peak 
intensity to the right-hand side. The pDI and zeta potential increased to 0.23 ± 0.12 and 29 ± 10 mV (Fig. 2d), 
respectively, indicating the successful conjugation of positively charged PLL on the surface of nanoparticles. The 
encapsulation efficiency of melatonin inside nanoparticles was determined as 44 ± 12% (Table 1).
Fourier-Transform Infrared Spectroscopy (FT-IR) for the determination of PLL and Trolox con-
jugation to PLGA nanoparticles. PLL-Trolox conjugation to PLGA nanoparticles was accomplished 
by reacting amine groups of PLL with carboxyl groups (-COOH) in PLGA. FTIR studies were carried out to 
characterize the related structural modifications (Fig. 3). PLGA spectra’s absorbance peaks appear strong at 
1,765–1,720 cm−1 for ester carbonyl and carboxyl C=O stretch, ether C-O-C stretch absorbance peak at 1,290–
1,180 cm−1, and secondary alcohol C-O stretch at 1,124–1,087 cm−1 (Fig. 3a). Broad medium absorbance peak of 
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PLGA alkyl C-H stretch at 3,000–2,840 cm−1 and alcohol O-H at 3,550–3,200 cm−1. PLL’s spectra present strong 
amide C=O stretch peak at 1,680–1,640 cm−1, a broad, strong primary and secondary N-H stretch peak at 3,500–
3,250 cm−1 and 3,350–3,310 cm−1, respectively (Fig. 3b). Also, a broad medium bend of PLL alkyl C-H stretch 
peak and amine N-H stretch appear correspondingly at 3,000–2,840 cm−1 and 1,650–1,540 cm−1. Trolox spec-
tra shows strong phenol O-H peak at 3,550–3,200 cm−1 and carboxylic C=O stretch peak at 1,720–1,706 cm−1 
(Fig. 3c). Numerous ether C-O-C peaks at 1,300–1,000 cm−1 and a broad, medium carboxylic O-H stretch peak 
at 3,300–2,500 cm−1 were observed. PLGA-PLL-Trolox composite spectrum displays strong secondary N-H, 
medium alkyl C-H, and amide C=O stretch peaks from PLL and strong phenol O-H, ether C-O-C stretch peaks 
from Trolox, and ester carbonyl C=O stretch and secondary alcohol C-O stretch peaks from PLGA, confirming 
the presence of three blocks in the synthesized composite (Fig. 3d).
Confirmation of the composition of PolyRad nanoparticles using 1H NMR Assay. Formation of 
melatonin-PLGA-PLL-Trolox nanoparticles was evaluated using 1H-NMR (Fig. 4). The NMR results depicted a 
successful conjugation of PLL-Trolox on melatonin encapsulated PLGA nanoparticles to form PolyRad nanopar-
ticles compared to their independent control NMR peaks (melatonin, PLGA, PLL, and Trolox alone). In Fig. 4, 
proton peaks at 2.5 and 7.25 ppm represent solvent background signals from DMSO-d6 and d-Chloroform, while 
the broad peak at 3.25 ppm represents residue water proton peak. Proton peaks from PLL, denoted by a, b, c 
and d which correspond to -CH-, -NH-, -CH2-, and -NH2 groups occurred at 1.7, 3.5, 4.75 and 5.2 ppm, respec-
tively. Also, melatonin distinctive peaks denoted by letters ‘e-n’ correspond to the -CH3-, the two -CH2-, -CH3O-, 
the three phenyl -CH-, the cyclic -CH-, and the two -NH- respectively. These peaks were recorded at 1.8, 2.75, 
3.25, 3.75, 6.75–7.25, 7.25, 7.8 and 11.6 ppm, respectively. For Trolox, distinctive peaks were lettered ‘o-v’. Trolox 
1H-NMR peaks showed propionic acid -CH3- (o) and -OH- (p) protons at 1.5 and 1.75 ppm respectively, cyclic 
-CH2- (q and r) at 1.9–2.1 ppm, phenyl methane protons (s, t and u) at 2.0–2.2 and 2.6 ppm, and the phenyl -OH- 
(v) protons at 7.25 ppm. Proton peaks for PLGA were labeled from ‘w-z’ and then ‘#’. PLGA proton peaks dis-
played lactide -CH3- (w), -CH- (y), and glycolide -CH2- (x) protons at 1.5, 6.2 and 5.5 ppm respectively. However, 
the lactide end and the glycolide end -OH- protons (z and # respectively) in PLGA were missing probably by 
being lost to neighboring protons. Comparing with the 1H-NMR of the individual components, 1H-NMR of 
nanoparticles displayed virtually all the peaks that were shown in the individual components as shown in Fig. 4. 
However, the chemical shift of protons (b) in PLL formed an amide bond with the lactide end -OH- protons (z) 
of PLGA, hence we had that this amide bond occurred around 3–3.5 ppm in the NPs’ 1H-NMR. Likewise, proton 
peak at 5.25 ppm in the NPs’ 1H-NMR corresponds to the -NH- group of the corresponding amide bond (CONH) 
between primary amino group of PLL (d) and the carboxyl group of Trolox (p).
Figure 2. Characterization of PolyRad nanoparticles. (a) Size of melatonin encapsulated PLGA nanoparticles; 
(b) Zeta potential of melatonin encapsulated PLGA nanoparticles; (c) size of melatonin-PLGA-PLL-Trolox 
conjugates; and (d) Zeta potential of melatonin-PLGA-PLL-Trolox conjugates. The three colors in each graph 
represent three independent experiments.
Initial mass of 
melatonin, M0 
(μg)
Melatonin concentration in 
unwashed suspension, Mu 
(μg/ml)
Melatonin concentration in 
supernatant, Ms (μg/ml)
Encapsulated melatonin, 
− −M M M( )u s0  (μg)
Encapsulation 
efficiency (%)
7500 200 ± 46 122 ± 54 4410 ± 1261 44 ± 12
Table 1. Percent encapsulation efficiency of melatonin in PolyRad nanoparticles.
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Figure 3. FTIR spectroscopy for investigation of melatonin-PLGA-PLL-Trolox nanoparticles. FTIR spectra 
analysis was performed to confirm the conjugation of PLL and Trolox to the surface of PLGA nanoparticles. (a) 
PLGA alone, (b) PLL alone, (c) Trolox and (d) PLGA-PLL-Trolox nanoparticles.
Figure 4. 1H-NMR to characterize melatonin, PLGA, PLL and Trolox in PolyRad nanoparticles. 1H-NMR 
spectra acquired at room temperature for PLL, melatonin, Trolox, PLGA and melatonin-PLGA-PLL-Trolox 
nanoparticles to confirm the nanoparticle structure.
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Scavenging capacity of Trolox using fluorometric HOSC assay. Trolox serves as a potent scaven-
ger of OH• radicals, efficiently blocks the effects of highly reactive free radicals even at low concentration and 
therefore, is tested to prevent the photochemical degradation of melatonin in PolyRad nanoparticulate form. 
Fluorometric Hydroxyl Radical Scavenging Capacity (HOSC) was performed to analyze the OH• scavenging 
capacity of Trolox in its free solution. Results showed that an increase in Trolox concentration in the HOSC 
medium increased the free radical scavenging capacity of Trolox. Figure 5 shows the fluorescence decay curve 
of fluorescein with time in the presence of different Trolox concentrations. In the absence of Trolox (Blank), the 
fluorescence intensity of fluorescein was quenched rapidly with more than 50% reduction in the relative fluores-
cence intensity within 10 min, indicating the reaction of fluorescein with OH• radicals caused by the Fenton like 
Fe3+/H2O2 system. Trolox worked as OH• radical scavenging agent that delayed the decay in fluorescence inten-
sity of fluorescein by diminishing the quenching rate significantly in a dose-dependent manner. As the Trolox 
concentration was increased from 20 to 100 μM, the capacity for scavenging OH• radicals increased. The ~100% 
fluorescence intensity retention time were 10, 50, 80, 100 and 120 min using 20, 40, 60, 80 and 100 μM Trolox, 
respectively.
Effects of photochemical degradation on PolyRad. To study the effect of photochemical oxidation on 
the structure of melatonin in PolyRad formulation, irradiation experiments were performed on PolyRad suspen-
sions using H2O2 in 40% acetonitrile-60% water solvent followed by UV light exposure. Bare melatonin was used 





2 2  that degrades melatonin12,15. The influence of H2O2 and UV on melatonin degradation was ana-
lyzed with time using HPLC (Fig. 6a). The melatonin peak did not change by more than ~20% by UV treatment 
only for 2 h (Fig. 6a; hatched column). UV irradiation in the presence of H2O2 influenced the disappearance of the 
melatonin peak by ~80% within 2 h (Fig. 6a; filled column). Pure melatonin control showed only one characteris-
tic peak with a retention time of 5.67 min eluted from the HPLC column (Fig. 6b). The photochemical degrada-
tion of melatonin (N-acetyl-5-methoxytryptamine) formed two major degradant peaks (B and C) at 4.7- and 
1.98-min retention times for N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and 6-hydroxymelatonin, 
respectively4,59–61. The measured changes of AFMK and 6-hydroxymelatonin concentrations increased as a func-
tion of different UV exposure time in the presence of H2O2 (SI Figs. 2–4). Also, a peak at ~ 3.95 min, likely due to 
the melatonin degradation product, N-acetyl-5-methoxykynuramine (AMK) is seen. The overall reaction fol-
lowed a first-order reaction: r kCMelatonin melatonin− = , where rMelatonin− , k and Cmelatonin represent the rate of disap-
pearance of melatonin, reaction rate constant and concentration of melatonin, respectively (SI Fig. 5). The 
reaction rate constant (k) is determined as × − −min(8 10 )5 1 (SI Fig. 5a). In contrast to bare melatonin (Fig. 6c, 
hatched column), a remarkable reduction of melatonin degradation was observed using PolyRad nanoparticles 
(Fig. 6c, filled column). PolyRad protected ~75, 65, 55 and 15% of the active structure of melatonin after UV 
irradiation only, and 2 h of UV followed by 0.75, 1, and 5 mM of H2O2 exposure, respectively indicating that nan-
oparticles scavenged H2O2 in a concentration-dependent manner. Encapsulation of melatonin using PolyRad 
nanoparticles reduced the formation of AFMK by ~50% (SI Fig. 6).
1H-NMR spectrometry studies on molecular structure of melatonin after gamma radiation. 
Based on the 1H NMR spectrum of melatonin as presented in Fig. 7a and Table 2, major melatonin peaks are 
observed at 1.9 (NHCOCH3), 2.9 (CH2), 3.5 (CH2NH), 3.9 (OCH3) and 6.9–7.4 ppm (benzene aromatic rings and 
Figure 5. Fluorescence decay curve of fluorescein in the absence and presence of Trolox to determine Trolox’s 
radical scavenging capacity. The relative fluorescence intensity of fluorescein was diminished by the OH• 
radical reactive oxygen species. Trolox is a free radical scavenging compound that removes OH• groups from 
the solution and returns the fluorescence intensity of fluorescein in a dose dependent manner. The relative 
fluorescence intensity lasted for ~10, 50, 80, 100 and 120 min in presence of 20, 40, 60, 80, and 100 μΜ Trolox, 
respectively.
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NHCHO). Free melatonin is degraded into other compounds that appear at 3.2, 3.6 and 3.78 ppm and predom-
inantly at 10.6 (OH•) and 10.9 (NHCO) ppm. Melatonin in PolyRad nanoparticles did not show any significant 
differences between the non-radiated control and gamma irradiated PolyRad samples. The percentage of active 
melatonin remaining was calculated using the integral ratio of peaks of groups I through V (Table 2) based on the 
non-radiated melatonin control (Fig. 7b). The structural integrity of melatonin alone was completely degraded 
to 25.7, 10.8 and 5.5% at 1, 5 and 10 Gy, respectively compared to non-radiated free melatonin. The nanoparticle 
plays a critical role in the protection of melatonin by >98% most likely by scavenging of free radicals generated 
from gamma radiation62.
Figure 6. PolyRad protects melatonin from photochemical degradation. (a) 2.5 μg melatonin was spiked with 
0.75 mM H2O2 followed by UV irradiation (254 nm) every 20 min for 2 h. Samples were freeze-dried, dissolved 
in 1 ml of 40% acetonitrile-60% water and analyzed using HPLC. The column graphs show the percent active 
structure of melatonin remaining after UV radiation only (hatched, open columns) and after H2O2 and UV 
treatments (black, filled columns). (b) The changes in melatonin peak areas after H2O2 and UV treatments. 
(c) PolyRad (black columns) was exposed to 0.75 mM H2O2 and UV treatments for longer exposure time for 
up to 8 h to find what percentage of melatonin is protected by PolyRad compared to bare melatonin (hatched 
columns). The columns represent mean of n = 3 and error bars denote standard deviation (SD).
Figure 7. The effects of gamma irradiation on melatonin using 1H-NMR spectroscopy. (a) Melatonin 
degradation was observed at 1, 5 and 10 Gy doses using a Co-60 source. The structure of melatonin alone 
without radiation is shown as a control. (b) The areas under the curve of 1H NMR peaks were integrated to 
determine the percentage melatonin degradation. Experiments were performed at least in triplicate to estimate 
the mean and standard deviation of each peak area.
Peak center (ppm) 1.9 2.9 3.5 3.9 6.9–7.4 10.6 10.9
Symbol I II III IV V VI VII
Chemical identity -NHCOCH3 -CH2 CH2NH OCH3 C6H6; NHCHO OH• -NHCO
Table 2. Identification of 1H NMR peaks of the molecular structure of melatonin after Co-60 gamma radiation.
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In vitro drug release kinetics. The melatonin release kinetics from PolyRad is shown in Fig. 8a before and 
after radiation. A total of 70% melatonin was released from non-radiated nanoparticles after 72 h at pH 7.4. 
Notably, more than 50% of the drug was released after only 2 h, suggesting a spontaneous rapid degradation of 
solid nanoparticles under physiological conditions. Exposure to radiation elicited higher drug release, reaching 
>90% drug release in 72 h. The drug release profile follows a biphasic pattern, indicating a controlled drug release 
mechanism. The data from in vitro experiments were fitted to a power-law model to investigate the kinetics of 
melatonin release (Fig. 8b and Table 3). The cumulative release is linear with respect to time, t ( > .R 0 972 ) where 
diffusion exponent n varies between 0.1–0.3, indicating a Fickian diffusion profile. The rate constant (k) varies 
between 0.3–0.4 suggesting a slow melatonin release from PolyRad.
Cytotoxicity assay. The effects of melatonin solution, PolyRad without melatonin and PolyRad (with mel-
atonin) on the viability of HUVEC were analyzed using MTT assay and live/dead assay imaging (Fig. 9). As the 
concentration of melatonin in PolyRad (♦) increases, cell viability decreases from 75% to ~60% at melatonin 
concentrations ranging from 0.01 to 10 mg/ml. Free melatonin (■) showed ~90% cell viability at 0.01 mg/ml which 
dropped to ~65% at 10 mg/ml. Independent radiation treatments using gamma (×) and UV irradiation (+) after 
Figure 8. In vitro release profiles of melatonin from PolyRad. (a) In vitro release curves of melatonin from 
PolyRad in PBS of pH 7.4 at 37 °C before (open circle, dotted line) and after the photochemical degradation 
(solid circle, solid line) of PolyRads. (b) Melatonin release data were fitted to power law models before and after 
photochemical degradation of PolyRads. The column bar represents the mean value with standard deviations 
for n = 3 independent experiments.
PolyRad Model Equation R2 Rate constant, k
Diffusion 
exponent, n
Non-radiated y = 1.5 + 0.1x 0.96 0.32 .0 1
Photochemical irradiation y = 1.6 + 0.2x 0.98 0.40 .0 2
Table 3. Kinetic modeling of melatonin release from PolyRad nanoparticles.
Figure 9. Effect of melatonin on HUVEC cell viability. (a) MTT assay shows that PolyRad is non-toxic at 
concentrations of ≤ 0.01 mg/ml. Data represents mean and standard deviation of three independent 
experiments. (b) Calcein AM (green fluorescence) and EthD-1 (red fluorescence) live/dead assay stain live and 
dead HUVEC, respectively after 0.01 mg/ml of PolyRad incubation.
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H2O2 exposure showed similar effects on cell viability as non-radiated PolyRad, indicating radiation did not affect 
the release of melatonin from the nanoparticles. Melatonin free PolyRad (•) had no significant toxicity at 0.01 
and 0.1 mg/ml, the cell viability dropped to ~65% at 10 mg/ml. Results show an increased melatonin cytotoxicity 
in the order of free melatonin, non-irradiated PolyRad and irradiated PolyRad. We further studied if melatonin 
and PolyRad interfered with the cell viability of HUVEC. As shown in Fig. 9b, live cells after treated with 0.01 mg/
ml each of melatonin and PolyRad fluoresce green as stained with calcein AM. Cells show a slight cytotoxicity as 
assessed by dead cell staining (red fluorescence) using EthD-1.
Discussion
Melatonin is an endogenous neurohormone that regulates many biological functions such as sleep, circadian 
rhythm, immune responses and cardiac functions, among others63–66. Changes of environment in spaceflight 
compared to that on Earth disrupt sleep and circadian clock in astronauts’ physiology decreasing the perfor-
mance1,67,68. Sleep medications such as melatonin are used to improve astronauts’ circadian rhythms and sleep4. 
Space medication is a challenge because of the instability of active pharmaceutical ingredients (API) in the pres-
ence of harsh spaceflight environmental conditions. Altered physical and chemical stability in pharmaceuticals 
can result in reduced potency which can result in reduced efficacy. It has been tested that the API of melatonin 
degrades in the adverse environments of space station4,60. The traditional approach to overcome the limitation 
is to replace medicines from the International Space Station (ISS) before their expiration. However, this is not a 
practical solution for longer duration missions to planets (e.g., Mars). Hence, it is desired that medicines main-
tain their shelf-life throughout the duration of the space mission. Contrary to standard dispensing practices on 
Earth, pharmaceuticals are packed and dispensed in special flight-certified containers and stored inside com-
pactly packed kits. The packaging could affect the active pharmaceutical ingredients and therapeutic efficacy 
of medications in space60,69. The shielding material should meet the requirement of application in radiotherapy, 
should be light-weight, flexible, environmental friendly and easily recyclable. According to these requirements, 
there is a need to provide effective shielding against space medications with materials of appropriate designs that 
can maintain the stability of space medicines.
Our results show that antioxidant conjugated polymeric nanoparticles (PLGA-PLL-Trolox) can act as an 
effective and protective shield for pharmaceuticals that are being exposed to high energy radiations in space. 
Trolox antioxidant effectively acts as a radiation-induced highly reactive OH• scavenger that protects the phar-
maceuticals prolongating the shelf-life and thus the potency. Trolox can scavenge free radicals through a vari-
ety of reaction mechanisms, as it is the case for many other scavengers62. Four reaction mechanisms have been 
reported to significantly contribute to the OH• scavenging capacity of Trolox in aqueous solution: hydrogen 
transfer (HT), radical adduct formation (RAF), single electron transfer (SET) and sequential proton loss electron 
transfer (SPLET)62. The free radical scavenging capacity of Trolox has been shown to reduce oxidative stress in 
aqueous systems as well as epithelial cells, hepatic injury and red blood cells in vitro and in vivo70–74. Fluorescein, 
organic compound used in this assay, has characteristic of high photostability, stability at physiological pH and is 
highly sensitive to OH• attacks. Accordingly, Trolox protected fluorescein from OH• attacks by scavenging the 
radicals, prolonging the relative fluorescein intensity. Figure 5 shows that conjugation of Trolox to the surface of 
drug-loaded PolyRad leads to successful shielding of encapsulated pharmaceuticals from the damaging effects 
of photochemical degradation. When PolyRads were photochemically degraded using UV light and H2O2, part 
of their covalent bonds dissociated which in turn protected the active structure of melatonin (Fig. 6c). AFMK 
and 6-hydroxymelatonin appear to be the two main degradants of pure melatonin which is blocked in PolyRad 
formulations. The antiradical activity of PolyRad was further detected using gamma radiation and analyzed via 
1H NMR showing>98% protection of active melatonin structure in nanoparticles (Fig. 7a,b).
In vitro drug release follows a biphasic kinetics pattern. The in vitro release for non-irradiated PolyRad showed 
a burst release of ~20% of the encapsulated melatonin (Fig. 8a). The initial burst release decreased after photo-
chemical degradation. The polymer coating began to disintegrate, releasing ~65% and 75% of total melatonin 
from non-radiated and irradiated PolyRad, respectively after 24 h and ~70% and 85% from non-radiated and irra-
diated PolyRad, respectively after 72 h. The exponent, n, characteristic of the overall mechanism of drug release 
increased after photochemical degradation (Fig. 8b). The values of the exponent of time, n, indicating that the 
release of melatonin (high diffusivity) is at least partially controlled by the scission of the polymer. The in vitro 
data provide guidance for understanding the fundamentals of melatonin drug release. In vitro cell culture studies 
indicate that melatonin and PolyRad induce cytotoxicity to HUVEC in a dose-dependent manner (Fig. 9a)75,76. 
Generation of reactive oxygen species has been reported to promote apoptosis in HUVEC while maintaining 
normal redox homeostasis77,78. It is possible that PolyRad increases ROS production suggesting higher cell death 
at concentrations above 0.01 mg/ml (10 μg/ml). The ability of PolyRad to release melatonin was not affected after 
irradiation. PolyRad is as potent as free melatonin in eliciting therapeutic effects in HUVEC growth (Fig. 9b).
conclusion
Here, we have described a new technology for protection of pharmaceuticals against radiation induced damages 
(i.e., free radical exposure), which is likely to occur during space missions. We synthesized PolyRad nanoparti-
cles, 325 ± 21 nm in hydrodynamic diameter, using the emulsion solvent evaporation method by encapsulating 
melatonin within the nanoparticles to protect APIs from radiation damage. Conjugation of Trolox to the surface 
of PLGA nanoparticles significantly inhibited the photochemical degradation of active melatonin. Nonetheless, 
the current results are promising and continue to shed light on the inherent benefits of Trolox as an antioxidant 
that acts as a free radical scavenger to shield spaceflight pharmaceuticals from the deleterious effects of incident 
radiation and helps maintain their shelf-life and potency. PolyRad is demonstrated to be particularly useful for 
shielding space pharmaceuticals from the toxic effects of space radiation as induced by free radicals with the con-
jugation of antioxidants on the surface of the nanoparticles. Results from this research can be further extended to 
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cancer treatment by reducing oxidative stress and preventing the damage of normal cells caused by high-energy 
radiation therapy, which is used to shrink tumors and kill cancer cells.
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